The U.S. Food and Drug Administration has withdrawn emergency use authorization for the COVID-19 antibody drug Evusheld because the drug is not effective against the Omicron variants now dominating the nation.
Evusheld was designed to prevent COVID infection in people with compromised immune systems. The FDA authorized the drug in December 2021, before Omicron variants like XBB and XBB.1.5 began circulating.
However, people and facilities with stocks of Evusheld should not throw the drug away in case those old variants become prevalent again, the news release advised.
Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer: